Skip to main content
Kuros Biosciences Ltd. logo

Kuros Biosciences Ltd. — Investor Relations & Filings

Ticker · KURN ISIN · CH0325814116 LEI · 5299006U5POB2AVTT709 SW Manufacturing
Open in API
Filings indexed 207 across all filing types
Latest filing 2013-10-17 Report Publication Anno…
Country CH Switzerland
Listing SW KURN

About Kuros Biosciences Ltd.

https://kurosbio.com/

Kuros Biosciences is a life sciences company that discovers, develops, and delivers innovative biologic technologies focused on tissue repair and bone regeneration. The company's mission is to address unmet clinical needs for safer, faster, and more predictable bone healing. Its primary commercial product is MagnetOs, an advanced bone graft designed to enhance bone formation. The efficacy of MagnetOs is supported by a comprehensive global research program, "Project Fusion," which includes scientific, pre-clinical, and Level I human clinical studies. Kuros Biosciences serves surgeons and patients across multiple medical fields, including spine, extremities, trauma, and oncology, leveraging deep scientific expertise and collaboration with leading clinical experts.

Recent filings

Filing Released Lang Actions
Cytos Biotechnology Ltd announces hosting of Investor & Analyst Day in NYC
Report Publication Announcement Classification · 99% confidence The document is a corporate news release announcing that Cytos Biotechnology Ltd will host an 'Investor and Analyst R&D Day' in New York City. It details the purpose (presenting on lead program CYT003), features expert speakers, and provides webcast/dial-in details. This type of announcement, which promotes an upcoming event aimed at investors and analysts to discuss strategy and research, aligns best with an Investor Presentation (IP) or a general announcement. Since it is an announcement *about* an event where presentations will be given, and it is not the presentation itself, nor a formal regulatory filing like 10-K or ER, it is closest to an Investor Presentation (IP) if we consider the content being presented, or potentially a Regulatory Filing (RNS) if viewed purely as a general corporate news release. However, given the focus on presenting R&D and strategy to investors, 'Investor Presentation' (IP) is a strong fit for the *subject matter*. Since the document itself is the announcement of the event, and not the presentation materials, it could also be argued as a Report Publication Announcement (RPA) or RNS. Given the specific nature of the event (Investor & Analyst R&D Day), it is highly related to investor communication materials. I will classify it as an Investor Presentation (IP) as it directly relates to the content that will be presented to investors, which is the core purpose of the announcement, rather than a generic RNS.
2013-10-17 English
Cytos Biotechnology Ltd announces financing transaction
Share Issue/Capital Change Classification · 99% confidence The document is titled "Cytos Biotechnology Ltd announces financing transaction" and explicitly discusses a "planned financing transaction that will raise up to CHF 17.6 million by selling up to 6.3 million shares in a rights offering." It also mentions seeking shareholder approval for an "ordinary capital increase" at an upcoming meeting. These elements directly relate to fundraising, capital structure changes, and the issuance of new shares. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP) or potentially 'Share Issue/Capital Change' (SHA). Since the primary focus is the financing plan itself (raising capital via share sale), CAP is the most appropriate primary classification, although SHA is closely related. Given the context of a rights offering and capital increase announcement, CAP is selected.
2013-10-10 English
Cytos Biotechnology Ltd (SIX:CYTN) today presents additional results from its Phase 2a study of CYT003 for the treatment of allergic asthma
Regulatory Filings Classification · 99% confidence The document is a press release dated September 9, 2013, announcing 'additional results from its Phase 2a study of CYT003 for the treatment of allergic asthma.' It details clinical trial findings, mentions presentation at a congress, and includes forward-looking statements typical of corporate news. It is not a formal regulatory filing like a 10-K, nor is it a transcript (CT) or a formal dividend/share change notice. Since it is an announcement of research/clinical updates, it fits best under the general 'Regulatory Filings' (RNS) category as a corporate news release, or potentially an 'Investor Presentation' (IP) if it were the presentation itself, but this is the release *about* the presentation. Given the options, and that it's a general corporate update on research, RNS is the most appropriate fallback for non-standard announcements, although it strongly resembles an Earnings Release (ER) in format, it focuses purely on R&D results rather than comprehensive financial performance for a period. Since there is no specific category for 'Research Update Press Release', RNS serves as the best fit for a general corporate announcement not covered by other specific codes.
2013-09-09 English
Cytos Biotechnology Ltd: Second Quarter Report 2013 / Highlights
Earnings Release Classification · 100% confidence The document explicitly states in the title and body that it reports the "Second Quarter 2013 Financial Results" and provides detailed financial summaries for the "Three-month period from April 1 to June 30, 2013." This content aligns perfectly with the definition of a comprehensive financial report for a period shorter than a year. The classification code for this is 'IR' (Interim / Quarterly Report). Although it mentions the AGM approval, the primary focus and bulk of the document are the financial results. Q2 2013
2013-08-06 English
Cytos Biotechnology Ltd, Annual Shareholders' Meeting: Shareholders approved all proposals and resolutions. (with additional features)
AGM Information Classification · 99% confidence The document explicitly mentions 'Annual Shareholders’ Meeting' multiple times in the title and body, and states that 'Shareholders approved all proposals and resolutions.' The key phrase is 'Annual Shareholders’ Meeting' and the content confirms the outcome of this meeting. This directly corresponds to the definition of AGM Information (AGM-R). The document length (4163 chars) is substantial enough to be the announcement itself, not just a brief link notification.
2013-06-28 English
Cytos Biotechnology Ltd invites to the Annual Shareholders' Meeting 2013 (with additional features)
AGM Information Classification · 99% confidence The document explicitly states, "Cytos Biotechnology Ltd invites to the Annual Shareholders’ Meeting 2013" and later, "Cytos invites to the Annual Shareholders’ Meeting 2013". It provides the date and location for the AGM and includes a link to the invitation document. This content directly relates to the Annual General Meeting (AGM). Therefore, the classification should be AGM Information (AGM-R). The document length (4142 chars) is substantial enough to be the primary announcement, not just a brief RPA.
2013-06-06 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.